Activity of CYP3A and Genotypes of CYP3A5- and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 03 May 2010
At a glance
- Drugs Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Adverse reactions; Pharmacokinetics
- 03 May 2010 New trial record